Published Date: 22 Mar 2023
An LSU Health New Orleans study showed the value of single, focused Interprofessional Education (IPE)-based exercises in assisting young students of health professions to control or avoid alcohol use disorder (AUD).
Read Full NewsBaseline RV Dysfunction May predict Sotatercept response in PAH
The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.
Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.
The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.
1.
BTK Inhibitor Active in Half of Patients With Richter Transformation
2.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
3.
Research team uncovers the underpinnings of head and neck cancers
4.
Booze and Pancreatic Cancer Risk; From 'Hospice' to 'Hope'; Gen Z-ers Skip Screening
5.
Kate Middleton Announces Major Cancer Update
1.
Managing Hematoma: A Guide to Prevention and Treatment
2.
Age-Dependent Hematopoietic Stem Cell Dynamics
3.
Therapeutic Advances in Megakaryocyte-Directed Therapies
4.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
5.
Advanced Methods in Oncology in Daily Practice
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
From Guidelines to Practice: Hematology
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
4.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation